# TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab

> **NCT03856099** · PHASE2 · TERMINATED · sponsor: **PharmAbcine** · enrollment: 19 (actual)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** TTAC-0001

## Key facts

- **NCT ID:** NCT03856099
- **Lead sponsor:** PharmAbcine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-13
- **Primary completion:** 2022-07-15
- **Final completion:** 2022-07-15
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Subject recruitment issues and follow-up study plans
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03856099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03856099, "TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03856099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*